Vučković Sonja, Srebro Dragana, Vujović Katarina Savić, Vučetić Čedomir, Prostran Milica
Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Clinic of Orthopaedic Surgery and Traumatology, Clinical Center of Serbia, Belgrade, Serbia.
Front Pharmacol. 2018 Nov 13;9:1259. doi: 10.3389/fphar.2018.01259. eCollection 2018.
Cannabis has been used for medicinal purposes for thousands of years. The prohibition of cannabis in the middle of the 20th century has arrested cannabis research. In recent years there is a growing debate about the use of cannabis for medical purposes. The term 'medical cannabis' refers to physician-recommended use of the cannabis plant and its components, called cannabinoids, to treat disease or improve symptoms. Chronic pain is the most commonly cited reason for using medical cannabis. Cannabinoids act via cannabinoid receptors, but they also affect the activities of many other receptors, ion channels and enzymes. Preclinical studies in animals using both pharmacological and genetic approaches have increased our understanding of the mechanisms of cannabinoid-induced analgesia and provided therapeutical strategies for treating pain in humans. The mechanisms of the analgesic effect of cannabinoids include inhibition of the release of neurotransmitters and neuropeptides from presynaptic nerve endings, modulation of postsynaptic neuron excitability, activation of descending inhibitory pain pathways, and reduction of neural inflammation. Recent meta-analyses of clinical trials that have examined the use of medical cannabis in chronic pain present a moderate amount of evidence that cannabis/cannabinoids exhibit analgesic activity, especially in neuropathic pain. The main limitations of these studies are short treatment duration, small numbers of patients, heterogeneous patient populations, examination of different cannabinoids, different doses, the use of different efficacy endpoints, as well as modest observable effects. Adverse effects in the short-term medical use of cannabis are generally mild to moderate, well tolerated and transient. However, there are scant data regarding the long-term safety of medical cannabis use. Larger well-designed studies of longer duration are mandatory to determine the long-term efficacy and long-term safety of cannabis/cannabinoids and to provide definitive answers to physicians and patients regarding the risk and benefits of its use in the treatment of pain. In conclusion, the evidence from current research supports the use of medical cannabis in the treatment of chronic pain in adults. Careful follow-up and monitoring of patients using cannabis/cannabinoids are mandatory.
大麻已被用于医疗目的数千年。20世纪中叶对大麻的禁令阻碍了大麻研究。近年来,关于大麻用于医疗目的的争论日益激烈。“医用大麻”一词指的是医生推荐使用大麻植物及其成分(称为大麻素)来治疗疾病或改善症状。慢性疼痛是使用医用大麻最常被提及的原因。大麻素通过大麻素受体起作用,但它们也会影响许多其他受体、离子通道和酶的活性。在动物身上使用药理学和遗传学方法进行的临床前研究增进了我们对大麻素诱导镇痛机制的理解,并为治疗人类疼痛提供了治疗策略。大麻素镇痛作用的机制包括抑制神经递质和神经肽从突触前神经末梢的释放、调节突触后神经元的兴奋性、激活下行抑制性疼痛通路以及减轻神经炎症。最近对研究医用大麻在慢性疼痛中应用的临床试验进行的荟萃分析提供了一定数量的证据,表明大麻/大麻素具有镇痛活性,尤其是在神经性疼痛方面。这些研究的主要局限性包括治疗时间短、患者数量少、患者群体异质性、对不同大麻素的研究、不同剂量、使用不同的疗效终点以及可观察到的效果有限。大麻短期医疗使用中的不良反应通常为轻至中度,耐受性良好且为一过性。然而,关于医用大麻长期安全性的数据很少。必须进行更大规模、设计更完善、持续时间更长的研究,以确定大麻/大麻素的长期疗效和长期安全性,并就其用于治疗疼痛的风险和益处向医生和患者提供明确答案。总之,当前研究的证据支持医用大麻用于治疗成人慢性疼痛。必须对使用大麻/大麻素的患者进行仔细的随访和监测。
Front Pharmacol. 2018-11-13
Curr Neurol Neurosci Rep. 2018-6-19
Ann Med. 2016
Rambam Maimonides Med J. 2020-1-30
Curr Rheumatol Rep. 2017-10-5
Pharmaceuticals (Basel). 2025-7-24
Commun Med (Lond). 2025-7-16
Neuropsychopharmacol Rep. 2025-9
Pharmacol Ther. 2018-6-15
Cochrane Database Syst Rev. 2018-3-7
J Health Econ. 2018-2-3
Expert Opin Drug Saf. 2018-1
Curr Rheumatol Rep. 2017-10-5
Cannabis Cannabinoid Res. 2017-6-1
Cannabis Cannabinoid Res. 2017-5-1
Cannabis Cannabinoid Res. 2017-3-1
Neuropsychopharmacology. 2017-8-30